Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Losartan and eprosartan are both angiotensin II receptor type 1 (AT1) antagonists, also known as angiotensin II receptor blockers (ARBs). They work by selectively blocking the binding of angiotensin II to AT1 receptors, reducing blood pressure by preventing vasoconstriction and aldosterone release. While they share the same primary mechanism of action, they have some pharmacological differences. Losartan has uricosuric properties, specifically inhibiting urate transporter 1 (SLC22A12, URAT1), which can increase uric acid excretion. Studies comparing these two medications have shown they produce similar blood pressure reductions in patients with hypertension and metabolic syndrome, and both have a neutral effect on fasting and post-fructose load serum uric acid concentration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on losartan + eprosartan.